Formycon AG (FSB: FYB, Prime Standard) will publish its financial results for the fiscal year 2025 on April 22, 2026. The Management Board will discuss the company’s development, key financial figures, and provide an outlook for the 2026 fiscal year during a live webcast conference call scheduled for Wednesday, April 22, 2026, at 3:00 PM (CEST) in English. Participants can register at https://webcast.meetyoo.de/reg/lNibT8TVWubG to receive dial-in details. The presentation and audio broadcast will be accessible via https://www.webcast-eqs.com/formycon-2025-fy. After the presentation, the Management Board will take questions from analysts. The recording will be available on the Formycon website at https://www.formycon.com/en/investor-relations/publications/.
In the second quarter of 2026, Formycon representatives will attend several investor conferences. On May 11–12, CFO Enno Spillner will participate in the Equity Forum Spring Conference in Frankfurt, Germany. On May 28, the company will publish its first quarter 2026 results, followed by a conference call with CEO Dr. Stefan Glombitza, CFO Enno Spillner, CBO Nicola Mikulcik, and CSO Dr. Andreas Seidl. From June 2–4, CFO Spillner will attend the Jefferies Global Healthcare Conference in New York City. On June 8, the management team will host an mwb research Roundtable via webcast. The Annual General Meeting will take place on June 10 at Haus der Bayerischen Wirtschaft in Munich. Finally, on June 18, CFO Spillner will participate in the UBS Life Sciences Conference in London. The full financial calendar is available at https://www.formycon.com/en/investors/financial-calendar/.
Formycon is a leading independent developer of high-quality biosimilars, focusing on therapies in ophthalmology, immunology, immuno-oncology, and other key disease areas. The company covers almost the entire value chain from technical development to regulatory approval. With FYB201/ranibizumab and FYB202/ustekinumab already on the market, and FYB203/aflibercept approved by the FDA, EMA, and MHRA, Formycon continues to advance its pipeline, including FYB208/dupilumab. The company’s efforts are crucial in providing patients with access to affordable biopharmaceuticals, especially as patents on major biologics expire, opening a market opportunity estimated at over 200 billion US dollars globally by 2032. Biosimilars currently generate about 21 billion US dollars in sales, with analysts projecting growth to over 74 billion US dollars by 2030.
